Accordingly, our showing that not only lactate but also alanine can serve as early biomarkers of the inhibition may pave the way to a trial in lymphoma patients, given the clinical relevance of BTK inhibitors in MCL and other lymphomas, on one hand, and the late change in tumor volume induced by these inhibitors, on the other hand. Here, BTK is linked to mantle cell lymphoma.